drugset / Trial / NCT03058094
A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
Phase 3
Withdrawn
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
RandomizedCrossoverOpen-labelTreatment
Summary
A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI.
Timeline
- Start
- 2018-12
- Primary completion
- 2019-12
- Completion
- 2020-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abivertinib | Small molecule | 300 mg | Oral |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |